KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Research & Development: 2009-2024

Historic Research & Development for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $901.5 million.

  • Ionis Pharmaceuticals' Research & Development fell 0.91% to $217.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $881.5 million, marking a year-over-year decrease of 3.41%. This contributed to the annual value of $901.5 million for FY2024, which is 0.21% up from last year.
  • According to the latest figures from FY2024, Ionis Pharmaceuticals' Research & Development is $901.5 million, which was up 0.21% from $899.6 million recorded in FY2023.
  • Ionis Pharmaceuticals' Research & Development's 5-year high stood at $901.5 million during FY2024, with a 5-year trough of $535.1 million in FY2020.
  • In the last 3 years, Ionis Pharmaceuticals' Research & Development had a median value of $899.6 million in 2023 and averaged $878.1 million.
  • Data for Ionis Pharmaceuticals' Research & Development shows a peak YoY increased of 29.48% (in 2022) over the last 5 years.
  • Ionis Pharmaceuticals' Research & Development (Yearly) stood at $535.1 million in 2020, then grew by 20.25% to $643.5 million in 2021, then climbed by 29.48% to $833.1 million in 2022, then increased by 7.98% to $899.6 million in 2023, then rose by 0.21% to $901.5 million in 2024.